India, Sept. 14 -- Radiopharm Theranostics (RADX) announced that positive interim data from its U.S. Phase 2b imaging trial of 18F-RAD101 in patients with suspected recurrent brain metastases has been selected for a late-breaking oral presentation at the 31st Annual Meeting of the Society of Neuro-Oncology (SNO26), scheduled for November 12-15, 2026, in Philadelphia.
RAD101 is an investigational PET imaging small molecule targeting fatty acid synthase (FASN), which is overexpressed in cerebral metastases from solid tumors.
The product is being developed to help distinguish recurrent brain metastases from treatment-related changes following therapy.
Previously reported interim results showed 93% concordance between RAD101 PET and MRI acro...